• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

生长抑素受体表达肿瘤体积与转移性 GEP-NET 患者健康相关生活质量的关系。

Relationship between somatostatin receptor expressing tumour volume and health-related quality of life in patients with metastatic GEP-NET.

机构信息

Department of Surgery, Ystad Hospital, Ystad, Sweden.

Institute of Clinical Sciences, Lund University, Lund, Sweden.

出版信息

J Neuroendocrinol. 2022 Jun;34(6):e13139. doi: 10.1111/jne.13139. Epub 2022 Apr 29.

DOI:10.1111/jne.13139
PMID:35488399
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9285792/
Abstract

For patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET), health-related quality of life (HRQoL) is important. Meanwhile, whether tumour volume is associated with HRQoL is unknown. Hence, the aim of this study was to assess if total somatostatin receptor expressing tumour volume is correlated with HRQoL in patients with metastatic GEP-NET. Some 71 patients were included in the study. HRQoL and NET-specific symptoms were assessed with EORTC QLQ-C30 and EORTC GI.NET21. A summary score was calculated from the output of the QLQ-C30. Total somatostatin receptor expressing tumour volume was retrospectively evaluated on somatostatin receptor imaging with positron emission tomography-computed tomography ( Ga-DOTA-TATE/TOC PET-CT) in each patient. Simple and multiple linear regression were used to evaluate the correlation between tumour volume and HRQoL, controlling for potential confounders. No correlation was found between total somatostatin receptor expressing tumour volume and QLQ-C30 summary score. Weak positive correlations were found between total tumour volume and the specific symptoms dyspnoea, diarrhoea and flushing. To the best of our knowledge, this is the first study to evaluate the association between total somatostatin expressing tumour volume and HRQoL. Our results indicate that, while tumour volume is weakly associated with symptom severity of the carcinoid syndrome, other factors might impact more on overall HRQoL.

摘要

对于患有胃肠胰神经内分泌肿瘤(GEP-NET)的患者,健康相关生活质量(HRQoL)很重要。同时,肿瘤体积是否与 HRQoL 相关尚不清楚。因此,本研究旨在评估转移性 GEP-NET 患者中总生长抑素受体表达肿瘤体积是否与 HRQoL 相关。本研究纳入了 71 名患者。采用 EORTC QLQ-C30 和 EORTC GI.NET21 评估 HRQoL 和 NET 特异性症状。从 QLQ-C30 的输出中计算出综合评分。在每位患者的生长抑素受体成像中,采用正电子发射断层扫描-计算机断层扫描(Ga-DOTA-TATE/TOC PET-CT)回顾性评估总生长抑素受体表达肿瘤体积。采用简单和多元线性回归来评估肿瘤体积与 HRQoL 之间的相关性,同时控制潜在的混杂因素。总生长抑素受体表达肿瘤体积与 QLQ-C30 综合评分之间无相关性。总肿瘤体积与呼吸困难、腹泻和潮红等特定症状之间存在弱正相关。据我们所知,这是第一项评估总生长抑素表达肿瘤体积与 HRQoL 之间关联的研究。我们的研究结果表明,尽管肿瘤体积与类癌综合征的症状严重程度呈弱相关,但其他因素可能对整体 HRQoL 产生更大影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfea/9285792/d9dd12fb8d6d/JNE-34-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfea/9285792/d9dd12fb8d6d/JNE-34-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfea/9285792/d9dd12fb8d6d/JNE-34-0-g001.jpg

相似文献

1
Relationship between somatostatin receptor expressing tumour volume and health-related quality of life in patients with metastatic GEP-NET.生长抑素受体表达肿瘤体积与转移性 GEP-NET 患者健康相关生活质量的关系。
J Neuroendocrinol. 2022 Jun;34(6):e13139. doi: 10.1111/jne.13139. Epub 2022 Apr 29.
2
Tumour-to-liver ratio determined by [Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours.通过[镓]Ga-DOTA-TOC PET/CT测定的肿瘤与肝脏比值作为生长抑素类似物对高分化胃肠胰神经内分泌肿瘤患者疗效的预后因素。
EJNMMI Res. 2020 Jun 15;10(1):63. doi: 10.1186/s13550-020-00651-z.
3
Biodistribution and first clinical results of F-SiFAlin-TATE PET: a novel F-labeled somatostatin analog for imaging of neuroendocrine tumors.F-SiFAlin-TATE PET的生物分布及首次临床结果:一种用于神经内分泌肿瘤成像的新型F标记生长抑素类似物。
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):870-880. doi: 10.1007/s00259-019-04501-6. Epub 2019 Sep 6.
4
Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.胃胰神经内分泌肿瘤中生长抑素受体 2 免疫组织化学评分系统与 68Ga-DOTATATE 正电子发射断层扫描/计算机断层成像的相关性和比较。
Neuroendocrinology. 2022;112(4):358-369. doi: 10.1159/000517530. Epub 2021 Jun 2.
5
Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.生长抑素受体 PET 在神经内分泌肿瘤中的应用:68Ga-DOTA0,Tyr3-奥曲肽与 68Ga-DOTA0-兰瑞肽的比较。
Eur J Nucl Med Mol Imaging. 2013 Feb;40(3):364-72. doi: 10.1007/s00259-012-2286-6. Epub 2012 Nov 14.
6
Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.高分化转移性胃肠胰神经内分泌肿瘤的健康相关生活质量
Cancer Metastasis Rev. 2015 Sep;34(3):381-400. doi: 10.1007/s10555-015-9573-1.
7
68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.68Ga-DOTA-TOC 在神经内分泌肿瘤和正常组织中的摄取:PET/CT 中生理性摄取与病理性过程的鉴别。
Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):514-23. doi: 10.1007/s00259-012-2309-3. Epub 2013 Jan 5.
8
Clinical evaluation of [Ga]Ga-DATA-TOC in comparison to [Ga]Ga-DOTA-TOC in patients with neuroendocrine tumours.[Ga]Ga-DATA-TOC 与 [Ga]Ga-DOTA-TOC 用于神经内分泌肿瘤患者的临床评估比较。
Nucl Med Biol. 2019 Sep-Oct;76-77:1-9. doi: 10.1016/j.nucmedbio.2019.08.006. Epub 2019 Aug 28.
9
Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.⁶⁸Ga-生长抑素受体 PET/CT 分子成像及其与神经内分泌肿瘤生长抑素受体免疫组化的相关性。
Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1659-68. doi: 10.1007/s00259-011-1846-5. Epub 2011 May 31.
10
Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.基于¹⁷⁷Lu-DOTATATE的肽受体放射性核素治疗在转移性胃肠胰神经内分泌肿瘤中的应用:一项与原发肿瘤部位、肿瘤增殖指数及双示踪剂成像特征相关的多参数反应评估
Nucl Med Commun. 2016 Oct;37(10):1030-7. doi: 10.1097/MNM.0000000000000547.

引用本文的文献

1
Retrospective evaluation of the predictive value of tumour burden at baseline [ Ga]Ga-DOTA-TOC or -TATE PET/CT and tumour dosimetry in GEP-NET patients treated with PRRT.回顾性评估基线时[⁶⁸Ga]Ga-DOTA-TOC或-TATE PET/CT的肿瘤负荷及肿瘤剂量测定对接受肽受体放射性核素治疗(PRRT)的胃肠胰神经内分泌肿瘤(GEP-NET)患者的预测价值。
EJNMMI Rep. 2024 Aug 8;8(1):24. doi: 10.1186/s41824-024-00210-y.
2
Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives.胃肠胰神经内分泌肿瘤:当前的发展、挑战和临床观点。
Mil Med Res. 2024 Jun 4;11(1):35. doi: 10.1186/s40779-024-00535-6.
3
Prognostic Implications of PET-Derived Tumor Volume and Uptake in Patients with Neuroendocrine Tumors.

本文引用的文献

1
Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.Lu-Dotatate 联合长效奥曲肽与高剂量长效奥曲肽治疗肠神经内分泌肿瘤患者(NETTER-1):一项开放标签、随机、对照、III 期临床试验的最终总生存和长期安全性结果。
Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15.
2
Impact of Specific Bowel Symptoms on Quality of Life in Patients with Midgut Neuroendocrine Tumours.肠神经内分泌肿瘤患者特定肠道症状对生活质量的影响。
World J Surg. 2021 Sep;45(9):2793-2803. doi: 10.1007/s00268-021-06146-9. Epub 2021 May 9.
3
正电子发射断层扫描(PET)得出的肿瘤体积和摄取情况对神经内分泌肿瘤患者的预后影响
Cancers (Basel). 2023 Jul 12;15(14):3581. doi: 10.3390/cancers15143581.
Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review.胃肠胰肿瘤患者的生活质量:系统文献回顾。
World J Gastroenterol. 2020 Jul 7;26(25):3686-3711. doi: 10.3748/wjg.v26.i25.3686.
4
Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors.晚期神经内分泌肿瘤肝转移的非药物治疗选择
J Clin Med. 2019 Nov 7;8(11):1907. doi: 10.3390/jcm8111907.
5
Prognostic value of somatostatin receptor expressing tumor volume calculated from Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors.基于 Ga-DOTATATE PET/CT 计算的生长抑素受体表达肿瘤体积对分化型神经内分泌肿瘤患者的预后价值。
Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2244-2251. doi: 10.1007/s00259-019-04455-9. Epub 2019 Jul 27.
6
User's guide to correlation coefficients.相关系数用户指南。
Turk J Emerg Med. 2018 Aug 7;18(3):91-93. doi: 10.1016/j.tjem.2018.08.001. eCollection 2018 Sep.
7
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With Lu-Dotatate in the Phase III NETTER-1 Trial.在 III 期 NETTER-1 试验中,接受 Lu-Dotatate 治疗的进展性中肠神经内分泌肿瘤患者的生活质量与健康相关。
J Clin Oncol. 2018 Sep 1;36(25):2578-2584. doi: 10.1200/JCO.2018.78.5865. Epub 2018 Jun 7.
8
Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?正电子发射断层扫描中定义代谢肿瘤体积的当前方法:哪种更好?
Nucl Med Mol Imaging. 2018 Feb;52(1):5-15. doi: 10.1007/s13139-017-0493-6. Epub 2017 Sep 19.
9
Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours.肠系膜纤维化和小肠类癌姑息性手术。
Endocr Relat Cancer. 2018 Mar;25(3):245-254. doi: 10.1530/ERC-17-0282. Epub 2017 Dec 18.
10
Guideline for PET/CT imaging of neuroendocrine neoplasms with Ga-DOTA-conjugated somatostatin receptor targeting peptides and F-DOPA.镓-DOTA 偶联生长抑素受体靶向肽和 F-DOPA 的神经内分泌肿瘤 PET/CT 成像指南。
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1588-1601. doi: 10.1007/s00259-017-3728-y. Epub 2017 May 25.